Alx Oncology Holdings 

Yahoo Finance • 6 days ago

Friday 9/19 Insider Buying Report: AROC, ALXO

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. At Archrock, a filing with the SEC revealed... Full story

Yahoo Finance • 13 days ago

ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer

Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company’s Board of Directors and will step down from the Board to join ALX as Interim Chief M... Full story

Yahoo Finance • 27 days ago

ALX Oncology to Participate in Upcoming Investor Conferences in September

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat... Full story

Yahoo Finance • last month

Unusual volume stocks in Friday's session

In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look. [unusualvolume] TOP UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT EEIQ [https://www.chartmill.com/stock/quote/EEIQ/p... Full story

Yahoo Finance • last month

ALX Oncology doses first patient in phase 1 trial of EGFR cancer drug

SOUTH SAN FRANCISCO - ALX Oncology Holdings Inc. (NASDAQ:ALXO), a clinical-stage biotechnology company with a current market capitalization of $53 million, announced Tuesday that the first patient has been dosed in its Phase 1 clinical tri... Full story

Yahoo Finance • last month

Curious about the stocks that are showing activity after the closing bell on Monday?

The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today. [postmarket] AFTER HOURS GAINERS TICKER CHANGE COMMENT LASE [https://www.chartmill.com/stock/q... Full story

Yahoo Finance • last month

What's going on in today's session

Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT SNGX... Full story

Yahoo Finance • last month

Earnings call transcript: ALS Oncology Q2 2025 reports EPS miss

ALS Oncology Holdings (ALSN) reported its second-quarter 2025 earnings on August 12, revealing an earnings per share (EPS) of -0.49 USD, which fell short of the forecasted -0.43 USD. The company’s stock closed at 0.61 USD, with a slight de... Full story

Yahoo Finance • last month

ALX Oncology GAAP EPS of -$0.49 misses by $0.04

* ALX Oncology press release [https://seekingalpha.com/pr/20198601-alx-oncology-reports-second-quarter-2025-financial-results-and-provides-corporate-update] (NASDAQ:ALXO [https://seekingalpha.com/symbol/ALXO]): Q2 GAAP EPS of -$0.49 miss... Full story

Yahoo Finance • last month

ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update

– Data from ASPEN-06 trial highlights CD47 expression as a key predictive biomarker of greater response to evorpacept in HER2+ Gastric Cancer; updated data to be presented at a medical conference in Q4 2025 – Phase 2 ASPEN-Breast evorpace... Full story

Yahoo Finance • 4 months ago

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat... Full story

Yahoo Finance • 4 months ago

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat... Full story

Yahoo Finance • 7 months ago

Why ALX Oncology Holdings Inc. (ALXO) Soared on Thursday

We recently published an article titled Micro-, Small-Cap Firms Dominate Market Rally.In this article, we are going to take a look at where ALX Oncology Holdings Inc. (NASDAQ:ALXO) stands against the other stocks. The stock market pulled... Full story

Yahoo Finance • 7 months ago

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

– Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in patients with HER2-positive gastric cancer in an oral presentation at 2025 ASCO GI – Presente... Full story

Yahoo Finance • 8 months ago

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

Oral presentation at 2025 ASCO Gastrointestinal Cancers Symposium today highlights evorpacept as the first CD47 blocker to show substantial tumor response and a well-tolerated safety profile in a prospective randomized trialGreatest benefi... Full story

Yahoo Finance • 8 months ago

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings, Inc. (“ALX Oncology” or the “Company”), (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to trea... Full story

Yahoo Finance • 8 months ago

ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI

Webcast on January 23 at 1:00 p.m. PT/4:00 p.m. ET will review updated data from trial evaluating CD47-blocker evorpacept in HER2-positive gastric cancer SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdin... Full story

Yahoo Finance • 2 years ago

ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, t... Full story

Yahoo Finance • 2 years ago

ALX Oncology Announces November Investor Conference Participation

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today annou... Full story

Yahoo Finance • 2 years ago

ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, t... Full story